U.S. Markets close in 2 hrs 48 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,416.00+6.40 (+0.45%)
At close: 4:45PM BST
Sign in to post a message.
  • e
    eduardo r
    July 16 (Reuters) - GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as it bolsters its pipeline ahead of a split with its consumer healthcare venture.
  • e
    eduardo r
    Elliott would like to see a moratorium on profit and revenue-related bonuses unless management meets its 2026 targets of 5% profit growth and 10% turnover growth and raising the margin target from 30% to 32%.
    Elliot scores 1 - Walmsley 0. This is getting interesting . Something good is going to happen to this company in the short run. Knew Singer -Walmsley exchange of views would be good for shareholders. Imao.
  • J
    Johnfod
    What's with the big pre-market drop today??
  • e
    eduardo r
    Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate.
  • R
    Raviraj
    The track record for GSK under Dame Emma Wamsley;

    Glaxo shares have stagnated in recent years. The company’s American depositary receipts are down 3.5% over the past year, while the S&P 500 is up 35.5% over the same period, and the S&P 500 Healthcare index is up 24.9%.

    And while the S&P 500 has climbed 53.2% over the last three years, the price of Glaxo’s ADR has been effectively flat.

    On what basis has the GSK Board allowed her to continue as CEO. It is appalling.
  • S
    S
    Shares of Alector, Inc. ALEC surged after it announced a strategic global collaboration with GlaxoSmithKline plc GSK. The companies will co-develop progranulin (PGRN)-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease. Enrollment is currently underway for a phase III study on AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Per the terms, Alector will receive $700 million in upfront payments. In addition, it will be eligible to receive up to an additional $1.5 billion in clinical development, regulatory and commercial launch-related milestone payments.

    Alector will lead the global clinical development of AL001 and AL101 through a phase II proof-of-concept study. Thereafter, both companies will share developmental responsibilities for all late-stage clinical studies on the candidates. All costs for global development will be divided between the companies. Alector and Glaxo will be jointly responsible for commercialization in the United States and share profits and losses. Alector will lead commercial efforts associated with AL001 in orphan indications and Glaxo will lead the commercialization of AL101 in Alzheimer’s and Parkinson’s disease. Outside the United States, Glaxo will be responsible for the commercialization of AL001 and AL101 and Alector will be eligible for tiered royalties.
    Bullish
  • m
    mercy
    I would encourage newcomers to spend a few months developing a solid understanding of why Cryptocurrency is different. It's a revolution and it’s a money system that is beyond the control of any one or group of people and we’ve never had anything like that before. That is why newbies and stock holder need a maestro who could put them through and that's why I'm introducing Mr. Nolasco to everyone around here he can be reached via 𝕥𝕖𝕝𝕖𝕘𝕣𝕒𝕞 @Kanielnolasco12, he is the best, he's gonna guide you and with the help of his Signals and Volatilities, you'll get good returns and also better knowledge about Cryptocurrencies, they're lot of scammers here trying to lure people away with huge return on investment which turns out to be PONZI SCHEME.
    Neutral
  • j
    jazz
    No dividend???? That’s not correct. They are going to state this info on June 23rd.

    The company will split into two. I’m sure the Consumer Health unit will have a dividend. Probably lower than peers as it will have debt to pay down then move in line with peers. The Pharma unit will likely have one too.

    My guess is that the dividend will come in around 1.9-%2.5 combined for a year or two.

    Besides … the good stuff is not the dividend … it’s going to be 30% + upside in stock price being unlocked.

    These two stocking in 3 years will probably be worth $70-80 !!

    Enjoy the ride
    Bullish
  • e
    eduardo r
    Great news GKS dividend cut will be less than expected and that will enhance the growth of the newly created companies after the split. Walmsley and Singer's exchange of views are creating synergies for this enterprise to move on.
  • m
    mark
    Just sold all. Company stock down on up day too many occasions.
  • R
    Raviraj
    "Activist investor Elliott today launched its long-awaited bombshell gameplan for how GlaxoSmithKline should be revived and heavily hinted that boss Emma Walmsley should quit, repeatedly citing management’s “lack of credibility”. How true.
  • G
    Greg
    Has anyone any information on what SHAREHOLDERS are going to get when the company splits ?
    We already know the dividend is going down, but are GSK shareholders going to get all the shares of both companies ? GSK is keeping 20%, are all the remaining shares going directly to the shareholders ?
  • e
    eduardo r
    Great news GKS dividend cut will be less than expected and that will enhance the growth of the newly created companies after the split. I believe we need both Walmsley and Singer will make a great team together.
  • a
    a
    Good outlook. Emma resignation would have been the icing on the cake
  • R
    Raviraj
    "Elliott Investment Management urged GlaxoSmithKline Plc to beef up the pharma expertise in its top ranks, calling into question Chief Executive Officer Emma Walmsley’s leadership of the U.K. drugmaker"

    Please fire Emma Wamsley if GSK has to move forward. She is the worst performing CEO in the pharma industry, cant understand the Board's rationale of continuing with her at the helm.
  • J
    Johnfod
    What's with the 2% drop today??
  • E
    Edgar
    & there's me thinking this was a chat board about Glaxo....
  • B
    Bernie
    If Walmsley was a going to be a good CEO, we would know it by now. Time for her to hit the road.
  • e
    eduardo r
    Exactly two years ago GSK and AZN SP were both around 40 $. Which one do you think is undervalued? Paul Singer is not a genius but he is right. https://finance.yahoo.com/m/d3bdfc3c-0736-3da8-8aa5-eca8c348d395/glaxosmithkline-defends.html
  • E
    Edgar
    Anyone know what that massive volume spike was (& odd price dip) about an hour & a half ago.....? Very odd. 🤔🤔